In Vitro method for screening .beta.-amyloid deposition
AssigneesRegents of the University of Minnesota, President and Fellows of Harvard College
InventorsJohn E. Maggio, Patrick W. Mantyh
Life of this patent
Estimating the term…
Abstract
The present invention provides: a labelled .beta.-amyloid peptide or active fragment; a composition including the labelled .beta.-amyloid peptide or active fragment thereof and a pharmaceutical carrier; a method for identifying active fragments of .beta.-amyloid peptide; a method for labelling the .beta.-amyloid peptide or an active fragment thereof; methods of using the labelled peptide or peptide fragment for detecting or monitoring Alzheimer's disease in a patient; and methods for screening agents that enhance or inhibit .beta.-amyloid aggregation or deposition onto tissue or other amyloid substance, such as silk.
Claims9
An in vitro method of screening an agent capable of affecting the deposition of .beta.-amyloid peptide or peptide fragment thereof on tissue, comprising:
- (a) combining a sample of silk with an amount of a labelled .beta.-amyloid peptide or labelled active peptide fragment thereof, effective to bind with a tissue evidencing the presence of, amyloidosis, and with a potential deposition-affecting agent to be screened, for a time effective to allow binding of the labelled peptide or peptide fragment to the silk;
- (b) detecting the amount of labelled peptide or the labelled active peptide fragment thereof bound to the silk;
- and
- (c) assessing the effect of the agent on the deposition of the .beta.-amyloid peptide or peptide fragment.
Dependencies are inferred from the claim text.